Amneal Pharmaceuticals Files DEFA14A Proxy Materials

Ticker: AMRX · Form: DEFA14A · Filed: Apr 22, 2026 · CIK: 0001723128

Sentiment: neutral

Topics: proxy-filing, sec-filing, pharmaceuticals

Related Tickers: AMNL

TL;DR

AMNL filed proxy docs 4/22/26 - check for shareholder votes.

AI Summary

Amneal Pharmaceuticals, Inc. filed a DEFA14A on April 22, 2026, related to additional definitive proxy soliciting materials. The filing, with SEC Accession No. 0001193125-26-168237, contains 2 documents including the main DEFA14A filing and a graphic file. The company's mailing address is 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ 08807.

Why It Matters

This filing indicates Amneal Pharmaceuticals is providing additional materials for proxy solicitations, which could relate to upcoming shareholder votes or corporate actions.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not inherently indicate significant new risks for the company.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a DEFA14A filing?

A DEFA14A filing is used to provide additional definitive proxy soliciting materials or Rule 14(a)(12) material beyond what was initially filed.

When was this specific DEFA14A filing made by Amneal Pharmaceuticals?

This DEFA14A filing was made on April 22, 2026.

What is the SEC Accession Number for this filing?

The SEC Accession Number for this filing is 0001193125-26-168237.

Where is Amneal Pharmaceuticals, Inc. located?

Amneal Pharmaceuticals, Inc.'s mailing address is 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ 08807.

What type of company is Amneal Pharmaceuticals, Inc. based on its SIC code?

Based on its SIC code (2834), Amneal Pharmaceuticals, Inc. is in the Pharmaceutical Preparations industry.

Filing Details

This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 22, 2026 regarding Amneal Pharmaceuticals, Inc. (AMRX).

View full filing on EDGAR

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on Read The Filing